Zobrazeno 1 - 10
of 711
pro vyhledávání: '"Ruben A Mesa"'
Autor:
Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Amanda McNally, Ivana Gojo, Judith E. Karp, Ruben A Mesa, Lisa O. Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes
Publikováno v:
Haematologica, Vol 99, Iss 4 (2014)
Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias. To identify genes that are synthetically lethal w
Externí odkaz:
https://doaj.org/article/a9f91e8fd1fa48579be11cc0f2221060
Autor:
Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes, Klaus Geissler, Rami S. Komrokji, Jing Zhang, Ulrich Germing, David P. Steensma, Daniel H. Wiseman, Michael Pfeilstöecker, Chiara Elena, Nicholas C. P. Cross, Jean-Jacques Kiladjian, Michael Luebbert, Ruben A. Mesa, Guillermo Montalban-Bravo, Guillermo F. Sanz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Valeria Santini, Pierre Fenaux, Michael R. Savona, On Behalf of the MDS/MPN International Working Group
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and propensity of acute l
Externí odkaz:
https://doaj.org/article/7f2429ebc64243c3b202c0776a5e62a4
Autor:
Sarah F. Christensen, Robyn M. Scherber, Gina L. Mazza, Amylou C. Dueck, Nana Brochmann, Christen L. Andersen, Hans C. Hasselbalch, Ruben A. Mesa, Holly L. Geyer
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Patients with Philadelphia-negative Myeloproliferative Neoplasms (MPN) suffer from numerous symptoms and decreased quality of life. Smoking is associated with an increased symptom burden in several malignancies. The aim of this st
Externí odkaz:
https://doaj.org/article/b165180ffecd468dbab3c975d8ec7b58
Autor:
Ganqian Zhu, Huacheng Luo, Yang Feng, Olga A. Guryanova, Jianfeng Xu, Shi Chen, Qian Lai, Arati Sharma, Bing Xu, Zhigang Zhao, Ru Feng, Hongyu Ni, David Claxton, Ying Guo, Ruben A. Mesa, Yi Qiu, Feng-Chun Yang, Wei Li, Stephen D. Nimer, Suming Huang, Mingjiang Xu
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nucleophosmin (NPM1) gene mutation induces a specific gene expression program leading to acute myeloid leukaemia. Here, the authors show that mutant NPM1 activates a HOXB locus-associated long non-coding RNA which is essential for its associated onco
Externí odkaz:
https://doaj.org/article/3d1f0106667c417191762bec7de14450
Autor:
Lilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, Maria Zingariello, Fabrizio Martelli, Paola Verachi, Cara Clementelli, Jean-Francois Denis, Adeeb H. Rahman, Gilles Tremblay, John Mascarenhas, Ruben A. Mesa, Maureen O’Connor-McCourt, Anna Rita Migliaccio, Ronald Hoffman
Publikováno v:
JCI Insight, Vol 6, Iss 18 (2021)
Myelofibrosis (MF) is a progressive chronic myeloproliferative neoplasm characterized by hyperactivation of JAK/STAT signaling and dysregulation of the transcription factor GATA1 in megakaryocytes (MKs). TGF-β plays a pivotal role in the pathobiolog
Externí odkaz:
https://doaj.org/article/aa050974d8234556ab4fc5e42238e3c0
Autor:
Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilus, Joseph C. Cappelleri, Claire Harrison
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-16 (2019)
Abstract Background The goal of the research reported here was to understand the patient experience of living with myelofibrosis (MF) and establish content validity of the Modified Myeloproliferative Neoplasm Symptom Assessment Diary (MPN-SD). Method
Externí odkaz:
https://doaj.org/article/10037569fd8641a283e259003be29fc8
Autor:
Prithviraj Bose, Andrew T. Kuykendall, Carole Miller, Sandra Kurtin, Kyle Farina, Donald M. Harting, John O. Mascarenhas, Ruben A. Mesa
Publikováno v:
Expert Opinion on Pharmacotherapy. :1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7110cc8afb1bfe9fb8089c768a5936b8
https://doi.org/10.1080/14656566.2023.2213435
https://doi.org/10.1080/14656566.2023.2213435
Autor:
Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V. Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a850abe032c828055182ec36c5ab409
https://doi.org/10.1158/1078-0432.ccr-22-3192
https://doi.org/10.1158/1078-0432.ccr-22-3192
Autor:
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Publikováno v:
Mesa, R A, Hudgens, S, Floden, L, Harrison, C N, Palmer, J, Gupta, V, McLornan, D P, McMullin, M F, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, M L, Mead, A J, Ross, D M, Oh, S T, Perkins, A, Leahy, M F, Deheshi, S, Donahue, R, Klencke, B J & Verstovsek, S 2023, ' Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies ', Cancer Medicine . https://doi.org/10.1002/cam4.5799
Scientia
Scientia
Momelotinib; Myelofibrosis; Patient-reported outcomes Momelotinib; Mielofibrosi; Resultats informats pel pacient Momelotinib; Mielofibrosis; Resultados informados por el paciente Background Myelofibrosis (MF)-associated constitutional symptoms can se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfbb9cc40d930868fce1d2a253b5f47
https://doi.org/10.1002/cam4.5799
https://doi.org/10.1002/cam4.5799
Autor:
Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison
Publikováno v:
HemaSphere, Vol 5, Iss 5, p e553 (2021)
Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAK
Externí odkaz:
https://doaj.org/article/628243f171b943f09d35b8a02bf0dbf2